IRulya Therapeutics Inc.
IRLAHealthcare|Biotechnology|US
$31.00
+1.69 (+5.77%)
Tangible Book / Share
$17.69
Cash / Share
$18.91
Financials
Financial Snapshot
Market Cap
$31.5M
Enterprise Value
-$84.5M
Revenue (TTM)
$0.00
Net Income (TTM)
-$92.5M
Cash & Investments
$116.0M
Net Cash
$116.0M
Free Cash Flow (TTM)
-$47.0M
Operating CF (TTM)
-$46.9M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$116.0M
Quarterly Burn
$11.7M
Monthly Burn
$3.9M
Est. Runway
~9.9 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $7.3M | $71.7M | $99.9M | $133.8M | $106.8M | $90.2M | $75.1M | $40.8M | $17.8M | $116.0M | |
| Operating Cash Flow | -$9.8M | -$11.7M | -$33.3M | -$50.8M | -$62.9M | -$44.0M | -$18.3M | -$31.9M | -$41.4M | -$46.9M | |
| Free Cash Flow | -$9.9M | -$11.9M | -$33.3M | -$50.9M | -$63.1M | -$44.2M | -$18.5M | -$32.2M | -$41.8M | -$47.0M | |
| Capital Expenditure | -$77.0K | -$212.0K | -$55.0K | -$52.0K | -$180.0K | -$133.0K | -$160.0K | -$257.0K | -$352.0K | -$78.0K | |
| Financing Cash Flow | $7.8M | $75.9M | $77.4M | $118.9M | $6.8M | $707.0K | $143.0K | -$4.8M | $17.9M | $121.8M |
R&D Spending
R&D (TTM)
$33.0M
R&D Intensity
—
R&D Growth vs Prior
-6.8%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $9.1M | $10.1M | $30.2M | $61.3M | $60.8M | $25.2M | $9.4M | $18.6M | $35.4M | $33.0M | |
| SG&A | $1.3M | $2.0M | $9.0M | $17.6M | $29.5M | $26.0M | $17.7M | $17.6M | $15.0M | $27.8M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $45.0K | $51.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $142.0K | $36.0K | |
| Gross Profit | -$45.0K | -$51.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$142.0K | -$36.0K | |
| R&D | $9.1M | $10.1M | $30.2M | $61.3M | $60.8M | $25.2M | $9.4M | $18.6M | $35.4M | $33.0M | |
| SG&A | $1.3M | $2.0M | $9.0M | $17.6M | $29.5M | $26.0M | $17.7M | $17.6M | $15.0M | $27.8M | |
| Operating Income | -$10.4M | -$12.1M | -$39.2M | -$78.9M | -$90.3M | -$52.0M | -$34.6M | -$57.3M | -$50.4M | -$123.7M | |
| Interest Expense | $1.6M | $957.0K | $0.00 | $0.00 | $0.00 | $568.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$12.2M | -$12.5M | -$37.0M | -$76.8M | -$89.9M | -$51.9M | -$31.6M | -$56.7M | -$80.8M | -$94.6M | |
| Net Income | -$12.2M | -$12.5M | -$37.0M | -$76.8M | -$89.9M | -$51.7M | -$31.4M | -$56.8M | -$84.0M | -$92.5M | |
| EPS (Diluted) | -114.00 | -116.00 | -386.00 | -526.00 | -606.00 | -308.00 | -168.00 | -262.00 | -336.00 | -68.91 | |
| EBITDA | -$10.3M | -$12.1M | -$39.0M | -$78.6M | -$89.6M | -$51.0M | -$26.8M | -$36.0M | -$80.6M | -$72.3M | |
| Shares Out. (M) | 0.11 | 0.11 | 0.10 | 0.15 | 0.15 | 0.17 | 0.19 | 0.22 | 0.25 | 6.13 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.3M | $24.9M | $51.2M | $66.8M | $69.7M | $44.6M | $20.8M | $6.2M | $5.8M | $116.0M | |
| Short-Term Investments | $0.00 | $46.8M | $48.6M | $67.0M | $37.1M | $45.6M | $54.3M | $34.6M | $11.9M | $0.00 | |
| Total Current Assets | $7.5M | $72.6M | $106.1M | $137.9M | $111.7M | $93.7M | $77.4M | $44.0M | $22.9M | $123.4M | |
| Total Assets | $7.7M | $72.9M | $124.4M | $189.5M | $133.2M | $103.9M | $180.2M | $114.5M | $93.5M | $124.0M | |
| Total Current Liabilities | $1.8M | $1.5M | $8.9M | $17.0M | $14.2M | $3.1M | $9.6M | $7.3M | $43.2M | $8.5M | |
| Long-Term Debt | $7.2M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $13.4M | $14.3M | $330.0K | $0.00 | |
| Total Liabilities | $28.0M | $1.5M | $8.9M | $17.2M | $14.6M | $3.3M | $95.1M | $84.3M | $129.2M | $15.5M | |
| Stockholders' Equity | -$20.3M | $71.4M | $115.5M | $172.3M | $118.6M | $100.6M | $85.1M | $30.1M | -$35.7M | $108.5M | |
| Retained Earnings | -$20.3M | -$32.8M | -$69.8M | -$146.7M | -$236.6M | -$288.3M | -$319.6M | -$376.5M | -$460.5M | -$500.0M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.8M | -$11.7M | -$33.3M | -$50.8M | -$62.9M | -$44.0M | -$18.3M | -$31.9M | -$41.4M | -$46.9M | |
| Capital Expenditure | -$77.0K | -$212.0K | -$55.0K | -$52.0K | -$180.0K | -$133.0K | -$160.0K | -$257.0K | -$352.0K | -$78.0K | |
| Free Cash Flow | -$9.9M | -$11.9M | -$33.3M | -$50.9M | -$63.1M | -$44.2M | -$18.5M | -$32.2M | -$41.8M | -$47.0M | |
| Investing Cash Flow | -$77.0K | -$46.8M | -$17.7M | -$52.4M | $59.0M | $18.0M | -$5.8M | $21.9M | $23.2M | $26.3M | |
| Financing Cash Flow | $7.8M | $75.9M | $77.4M | $118.9M | $6.8M | $707.0K | $143.0K | -$4.8M | $17.9M | $121.8M | |
| Issuance of Stock | $0.00 | $75.7M | $77.8M | $117.6M | $6.8M | $608.0K | $149.0K | $225.0K | $17.9M | $127.4M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $7.8M | $250.0K | -$559.0K | -$34.0K | $0.00 | -$49.0K | -$6.0K | $0.00 | $0.00 | -$5.5M | |
| Stock Based Comp. | $38.0K | $155.0K | $2.1M | $14.5M | $29.9M | $16.6M | $5.2M | $4.7M | $5.1M | $15.8M | |
| Net Change in Cash | -$2.2M | $17.5M | $26.3M | $15.6M | $2.9M | -$25.1M | -$23.8M | -$14.5M | -$403.0K | $99.2M |
Dilution Tracker
Shares outstanding grew 71.7% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+71.7%
Stock Issuance (TTM)
$127.4M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.11 | 0.11 | 0.10 | 0.15 | 0.15 | 0.17 | 0.19 | 0.22 | 0.25 | 6.13 | |
| Change vs Prior % | — | 0.0% | -11.7% | 53.3% | 1.9% | 12.7% | 11.2% | 16.2% | 15.8% | 2348.4% | |
| Stock Issuance | $0.00 | $75.7M | $77.8M | $117.6M | $6.8M | $608.0K | $149.0K | $225.0K | $17.9M | $127.4M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $38.0K | $155.0K | $2.1M | $14.5M | $29.9M | $16.6M | $5.2M | $4.7M | $5.1M | $15.8M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 60.3% | -17.5% | -32.0% | -44.6% | -75.8% | -51.4% | -36.9% | -188.5% | 235.1% | -413.3% | |
| ROA % | -158.5% | -17.1% | -29.7% | -40.6% | -67.5% | -49.7% | -17.4% | -49.6% | -89.8% | -74.6% | |
| ROIC % | -174.1% | -17.0% | -33.9% | -45.7% | -75.4% | -51.1% | -20.2% | -53.4% | -73.7% | -104.6% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | -13.3% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -16.9% | -223.2% | -101.4% | -14.5% | 42.4% | 33.4% | -65.5% | 12.0% | |
| Net Income | 0.0% | -2.0% | -196.4% | -107.8% | -17.0% | 42.6% | 39.2% | -81.1% | -47.8% | |
| EPS (Diluted) | 0.0% | -1.8% | -232.8% | -36.3% | -15.2% | 49.2% | 45.5% | -56.0% | -28.2% | |
| Operating Cash Flow | 0.0% | -19.0% | -184.5% | -52.7% | -23.8% | 30.0% | 58.5% | -74.4% | -29.8% | |
| Free Cash Flow | 0.0% | -20.2% | -179.9% | -52.6% | -24.1% | 30.0% | 58.2% | -74.3% | -29.9% | |
| R&D Expense | 0.0% | 10.8% | 199.6% | 102.9% | -0.8% | -58.6% | -62.5% | 96.8% | 90.3% | |
| SG&A Expense | 0.0% | 60.0% | 340.2% | 96.4% | 67.9% | -11.9% | -32.0% | -0.6% | -14.4% | |
| Total Assets | 0.0% | 844.3% | 70.7% | 52.3% | -29.7% | -22.0% | 73.4% | -36.5% | -18.3% | |
| Book Value / Share | 0.0% | 452.2% | 83.1% | -2.7% | -32.4% | -24.7% | -23.9% | -69.5% | -202.3% | |
| Debt | 0.0% | -100.0% | 0.0% | 0.0% | 160.3% | -61.0% | 2949.4% | 7.2% | 24.7% | |
| Diluted Shares | 0.0% | 0.0% | -11.7% | 53.3% | 1.9% | 12.7% | 11.2% | 16.2% | 15.8% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B1.75
10Y Low / Med / High0.21 / 3.16 / 9.92
EV/EBITDA1.17
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$17.69
Net Current Assets / Share
$106.09
Graham Net-Net
$16.97
Cash / Share
$18.91
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -57.70 | -56.71 | -29.09 | -10.56 | -4.17 | -0.41 | -1.25 | -1.43 | -1.99 | -0.45 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -34.95 | 9.92 | 9.25 | 4.71 | 3.16 | 0.21 | 0.46 | 2.68 | -4.70 | 1.75 | |
| EV/EBITDA | -68.63 | -56.67 | -26.10 | -9.47 | -3.42 | 0.45 | -1.20 | -2.49 | -2.24 | 1.17 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-5.24
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Net Income | -$2.2M | -$1.1M | -$1.7M |
| EPS | $-9.20 | $-4.57 | $-4.72 |
| # Analysts (EPS) | 4 | 4 | 7 |